The three musketeers: uniting against CLL

Marwan Kwok^{1

2}, Tatjana Stankovic¹

Affiliations

Editorial

Marwan Kwok et al. Blood. 2022.

. 2022 Mar 3;139(9):1264-1265.

doi: 10.1182/blood.2021014826.

Marwan Kwok^{1

2}, Tatjana Stankovic¹

No abstract available

Comment on

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, Schneider C, Bloehdorn J, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S. Huber H, et al. Blood. 2022 Mar 3;139(9):1318-1329. doi: 10.1182/blood.2021013208. Blood. 2022. PMID: 35108374 Clinical Trial.